The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent ...
The drug offered more relief than a placebo in clinical trials, though it does not appear more effective than other pain ...